Moleac
11 Biopolis Way
Suite 09-07/08
Helios
138667
Tel: 65-6478-9430
Fax: 65-6478-9435
Website: http://www.moleac.net/
Email: contact@moleac.net
5 articles about Moleac
-
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
-
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
3/5/2018
Moleac, a biopharmaceutical company focused on research and development of new medicines for central nervous system (CNS) diseases and injuries, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for a Phase 1 study of MLC1501, as first step of a clinical programme in post-stroke recovery treatment.
-
Moleac Release: NeuroAiD Has Shown Persistent Long-Term Benefits After An Initial 3-Month Treatment Following Stroke Onset
6/10/2015
-
Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement
11/28/2011
-
Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia
6/28/2011